Dr. R.Deshaies Cal Tech, to Speak at Ubiquitin Research Conference Feb 25-26, 2013 in Las Vegas, NV
2012-12-12 07:08:58 - 3rd Ubiquitin Research and Drug Discovery Conference (Feb 25-26, 2013 Las Vegas, NV)
Dr. Deshaies is Professor and Executive Officer of Biology at the California Institute of Technology and an Investigator at the Howard Hughes Medical Institute. His career has focused on investigating the cellular machinery that mediates protein degradation by the Ubiquitin-Proteasome System (UPS), and how this machinery regulates cell division. Dr. Deshaies is a leading figure in the Ubiquitin field, has
published over 100 papers and is an inventor on nine U.S. patents, many related to his work on the UPS. For information on his work, visit www.its.caltech.edu/~rjdlab/
. Dr. Deshaies has received numerous awards and scholarships, including the Markey and Searle Scholar Awards and Burroughs-Wellcome and Beckman New Investigator Award; in 1999 he was selected as Young Investigator of the Year by the American Society for Cell Biology and in 2011 was elected to the American Academy of Arts and Sciences. In addition to being a co-founder of Cleave Biosciences, Dr. Deshaies was the academic co-founder of Proteolix, which was sold in October 2009 to Onyx in a deal valued at up to $851 million.
The 3rd Ubiquitin Research and Drug Discovery Conference will bring together a 50-50 mix of academic and industry experts from leading affiliations (such as Elan, Millenium, Genentech, Celgene, Novartis, Onyx, Amgen, Cal-Tech, Emory University, Harvard, University of Washington, UCLA, etc.) to cover many current and relevant aspects of the Ubiquitin Proteasome Sturcture, Ligases, Sumo and more.
This conference is also part of the 2nd Novel Cancer Therapeutic Summit, which consists of this track and two others:
4th Cancer Targets and Therapeutics
2nd Oncology Partnering and Deal Making
For more information, please visit www.gtcbio.com